Characteristics of the development and evaluation groups
| Development group (n=1500) | Evaluation group (n=1000) | |
| Period covered | 1/1/1995 to 31/12/1996 | 1/1/1997 to 1/3/1998 |
| Age (years) (mean (SD)) | 61 (10.3) | 62 (10.5) |
| Male/female | 68/32 | 75/25 |
| Stable angina | 46 | 43.4 |
| Stent rate | 54 | 63.5 |
| Abciximab administration | 0.5 | 5.12-150 |
| Diabetes | 8.6 | 11.2 |
| High cholesterol | 30.3 | 33.5 |
| Hypertension | 29.3 | 35.6 |
| Smoker | 21.4 | 26.7 |
| Ex-smoker | 22.7 | 24.2 |
| Renal failure | 0.7 | 0.5 |
| Previous CABG | 12.2 | 10.4 |
Values are per cent unless stated otherwise.
↵2-150 p < 0.05 (more abciximab was used in the evaluation group).